---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-088353"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:02:29.812169+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TELA Bio Q2 2024 revenue $16.1M (+11% YoY), net loss $12.6M; reiterates FY guidance

## Summary
- Revenue $16.1M, +11% YoY; net loss $12.6M vs $10.8M loss in Q2 2023.
- FY 2024 revenue guidance reiterated at $74.5M-$76.5M (27%-31% YoY growth).
- Appointed Greg Firestone as CCO on May 20 to boost commercial productivity.
- Launched robotically compatible OviTex IHR for inguinal hernia market in U.S.
- Expects $3M-$7M in total NIVIS revenue share payments over next eight quarters starting Q3 2024.

## SEC filing metadata
- accession: 0001104659-24-088353
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465924088353/0001104659-24-088353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465924088353/tm2421368d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-088353
- JSON: https://secwatch.observer/filing/0001104659-24-088353.json
- Plain text: https://secwatch.observer/filing/0001104659-24-088353.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.